Table 1.
Baseline subject characteristics
| Subject 1 | Subject 2 | Subject 3 | Subject 4 | |
|---|---|---|---|---|
| Sex | M | M | F | M |
| Age (years) | 79 | 69 | 64 | 60 |
| Height (m) | 1.82 | 1.82 | 1.69 | 1.9 |
| Weight (kg) | 73 | 99 | 99 | 94 |
| Body mass index (kg/m2) | 22.0 | 29.9 | 34.6 | 26.0 |
| Body surface area (m2) | 1.92 | 2.24 | 2.16 | 2.23 |
| LV ejection fraction (%) | 22 | 33 | 31 | 37 |
| NT-proBNP (pg/mL) | 3268 | 1430 | ||
| BNP (pg/mL) | 723 | 216 | ||
| Resting blood pressure (mmHg) | 100/61 | 156/95 | 105/56 | 110/65 |
| ECG rhythm | Sinus | Sinus | Sinus | Sinus |
| Beta blocker | 1 | 1 | 1 | 1 |
| ACEi/ARNi | 1 | 1 | 1 | 1 |
| Aldosterone inhibitor | 1 | 0 | 1 | 1 |
| SGLT2 inhibitor | 0 | 0 | 0 | 0 |
| Diuretics | 1 | 0 | 1 | 1 |
LV, left ventricle; NT-proBNP, N-terminal pro B-type natriuretic peptide; BNP, B-type natriuretic peptide; ACEi, angiotensin converting enzyme inhibitor; ARNi, angiotensin II receptor/neprilysin inhibitor; SGLT2, sodium/glucose transport protein 2.